Su YJ, et al. - In psoriatic patients with type 2 diabetes mellitus (T2DM), researchers studied the real-world safety of metformin using the National Health Insurance Research Database. Participants were randomized to metformin (n=5,520) or non-metformin (n=3,062) groups, according to metformin and other anti-diabetic medication prescriptions. According to findings, the metformin group and non-metformin group did not differ significantly in the risk of all-cause mortality, severe psoriasis, psoriasis-related admission, and re-admission of any-cause. Overall, the investigators suggested that metformin can be prescribed without safety concerns for diabetic psoriatic patients.